Radiculitis

Summary

Radiculitis (MONDO:0021765) is a disease with 10 GWAS associations across 13 studies and 3 clinical trials. Top therapeutic interventions include foscarnet and ganciclovir. A subtype of nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 10
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	radiculitis
Mondo ID	MONDO:0021765
NCIT	C78581
SNOMED CT	82473003
UMLS	C0034544
MedGen	11099
Is cancer (heuristic)	no

Also known as: Inflammation, Nerve Root · Nerve Root Inflammation · Nerve Root Inflammations · Radiculitides · radiculitis

Data availability: 10 GWAS associations (13 studies).

Disease family

This is a subtype of nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › radiculitis

Related subtypes (71): congenital nervous system disorder, central nervous system disorder, autoimmune disorder of the nervous system, cranial nerve neuropathy, peripheral nervous system disorder, neuronitis, diplegia of upper limb, retinal disorder, developmental disability, restless legs syndrome, movement disorder, toxic encephalopathy, Barre-Lieou syndrome, Gerstmann syndrome, drug-induced akathisia, drug-induced dyskinesia, stiff-person syndrome, Worster-Drought syndrome, corneal-cerebellar syndrome, pachygyria-intellectual disability-epilepsy syndrome, porencephaly-cerebellar hypoplasia-internal malformations syndrome, symmetrical thalamic calcifications, neonatal brainstem dysfunction, primary orthostatic hypotension, rippling muscle disease with myasthenia gravis, periodic paralysis, qualitative or quantitative protein defects in neuromuscular diseases, specific learning disability, cerebellar hypoplasia-tapetoretinal degeneration syndrome, locked-in syndrome, dopa-responsive dystonia, idiopathic recurrent stupor, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, spontaneous periodic hypothermia, Sydenham chorea, duplication of the pituitary gland, Balint syndrome, paraneoplastic neurologic syndrome, persistent idiopathic facial pain, serotonin syndrome, hypothalamic adipsic hypernatraemia syndrome, exercise-induced malignant hyperthermia, perineural cyst, neuromuscular disease, neuromyelitis optica, AL amyloidosis, AA amyloidosis, neuroleptic malignant syndrome, infectious disorder of the nervous system, central nervous system malformation, synaptopathy, nervous system neoplasm, sensory ganglionopathy, wet beriberi, perceptual disorders, prepubertal anorexia nervosa, neurocutaneous syndrome, neurovascular disorder, Wallerian degeneration, nervous system injury, neurosarcoidosis, neuroendocrine disorder, tubulinopathy, atactic disorder, hereditary neurological disease, meningitis-retention syndrome, KIF1A related neurological disorder, neurological pain disorder, neurodevelopmental disorder, post 5-alpha-reductase inhibitors treatment syndrome, post-selective serotonin reuptake inhibitor sexual dysfunction

Genetics & variants

GWAS landscape

10 GWAS associations across 13 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1245527	1e-17	CHST3 - SPOCK2	G	0.06
rs1245512	1e-17	CHST3 - SPOCK2	G	0.06
rs11635145	2e-16	SMAD3	A	0.05
rs13107325	1e-15	SLC39A8	C	0.1
rs2423289	3e-13	SRSF10P2 - HSPBAP1P1	T	0.08
rs7422275	7e-12	ANTXR1 - GFPT1	C	0.05
rs1579331	3e-08	ARLNC1	?
rs561598314	8e-08	RNU6-210P - RN7SKP123	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476268	Verma A	2024	44,425	380,967	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479106	Verma A	2024	24,303	408,753	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479100	Verma A	2024	14,267	99,200	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480572	Verma A	2024	14,267	99,200	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479105	Verma A	2024	9,222	105,937	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480573	Verma A	2024	9,222	105,937	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479098	Verma A	2024	6,255	50,110	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479104	Verma A	2024	3,171	54,212	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479099	Verma A	2024	540	6,009	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90044615	Jiang L	2021	444	455,904	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	4
intron_variant	3
missense_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1245527	10	72036394	G>C,T	0.413	intergenic_variant	CHST3 - SPOCK2	1e-17	Tier 4: intronic/intergenic
rs1245512	10	72042129	G>A,T	0.376	intergenic_variant	CHST3 - SPOCK2	1e-17	Tier 4: intronic/intergenic
rs11635145	15	67077783	A>G	0.443	intron_variant	SMAD3	2e-16	Tier 4: intronic/intergenic
rs13107325	4	102267552	C>A,T	0.083	missense_variant	SLC39A8	1e-15	Tier 1: coding
rs2423289	20	7836060	T>C	0.157	intergenic_variant	SRSF10P2 - HSPBAP1P1	3e-13	Tier 4: intronic/intergenic
rs7422275	2	69301565	C>A,T	0.384	intron_variant	ANTXR1 - GFPT1	7e-12	Tier 4: intronic/intergenic
rs1579331	16	80873455	G>A,C	0.05	intron_variant	ARLNC1	3e-08	Tier 4: intronic/intergenic
rs561598314	1	93023821	T>G		intergenic_variant	RNU6-210P - RN7SKP123	8e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00416117	PHASE2/PHASE3	COMPLETED	Manual Physical Therapy and Exercise for Mechanical Neck Disorders
NCT00000856	PHASE1	WITHDRAWN	A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.
NCT02941133	Not specified	UNKNOWN	Comparison of Neural Mobilization Techniques to Standard Care Treatment in Patients With Lumbar Radiculitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FOSCARNET	4	4
GANCICLOVIR	4	1